By Josh White
Date: Friday 31 Jan 2025
(Sharecast News) - Fusion Antibodies announced on Friday that its OptiMAL validation project with the US National Cancer Institute (NCI) was progressing as planned.
By Josh White
Date: Tuesday 08 Oct 2024
(Sharecast News) - Fusion Antibodies reported positive trading in an update on Tuesday, highlighting significant progress for the first half of its financial year.
By Josh White
Date: Thursday 05 Sep 2024
(Sharecast News) - Preclinical antibody discovery and engineering specialist Fusion Antibodies said in its final results on Thursday that despite a challenging year with a decline in revenue, it had strengthened its financial position and expanded its pipeline of opportunities.
Currency | UK Pounds |
Share Price | 6.30p |
Change Today | -0.050p |
% Change | -0.79 % |
52 Week High | 10.20 |
52 Week Low | 2.90 |
Volume | 579,817 |
Shares Issued | 113.66m |
Market Cap | £7.16m |
Beta | 0.01 |
RiskGrade | 464 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:29 | 7 @ 6.40p |
16:29 | 8 @ 6.40p |
15:28 | 175,000 @ 6.26p |
16:23 | 8 @ 6.40p |
16:16 | 7 @ 6.40p |
Chair | Simon Gordon Douglas |
CEO | Adrian Kinkaid |
You are here: research